Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report)’s stock price was up 4.3% during trading on Thursday after StockNews.com upgraded the stock from a sell rating to a hold rating. The company traded as high as $126.94 and last traded at $124.66. Approximately 64,418 shares changed hands during trading, a decline of 83% from the average daily volume of 387,802 shares. The stock had previously closed at $119.50.
ASND has been the topic of a number of other reports. Jefferies Financial Group lifted their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Citigroup dropped their price objective on Ascendis Pharma A/S from $193.00 to $178.00 and set a “buy” rating for the company in a research report on Wednesday. Bank of America boosted their target price on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Finally, Oppenheimer upgraded shares of Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and set a $180.00 price objective for the company in a research report on Thursday. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $187.08.
Read Our Latest Report on Ascendis Pharma A/S
Institutional Investors Weigh In On Ascendis Pharma A/S
Ascendis Pharma A/S Stock Up 0.1 %
The stock’s 50-day simple moving average is $134.38 and its 200 day simple moving average is $138.20. The firm has a market cap of $6.94 billion, a P/E ratio of -12.40 and a beta of 0.63.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Read More
- Five stocks we like better than Ascendis Pharma A/S
- What does consumer price index measure?
- Does GTA VI Make Take-Two Interactive Stock an Irresistible Buy?
- How to Calculate Return on Investment (ROI)
- Why HPE’s Dip Is a Prime Opportunity for Blue-Chip AI Investors
- Find and Profitably Trade Stocks at 52-Week Lows
- Why Analysts See Big Upside for Occidental Petroleum Despite Lows
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.